Tempus AI, Inc. (BCBA:TEM)
Argentina
· Delayed Price · Currency is ARS | Market Cap | 13.43T |
| Revenue (ttm) | 1.85T |
| Net Income (ttm) | -355.63B |
| Shares Out | n/a |
| EPS (ttm) | -2,040.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,994 |
| Average Volume | 7,942 |
| Open | 6,680.00 |
| Previous Close | 6,620.00 |
| Day's Range | 6,380.00 - 6,690.00 |
| 52-Week Range | 5,160.00 - 13,350.00 |
| Beta | n/a |
| RSI | 37.60 |
| Earnings Date | May 5, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USDNews
Tempus AI: Buy The Post-Earnings Dip
Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention ...
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley T...
Tempus AI: No AI Interruption Detected
Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organ...
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Tempus AI Stock Drops Despite Q4 Earnings Beat: Details
Tempus AI, Inc. (NASDAQ:TEM) shares fell in Tuesday's extended trading after the company released its fourth-quarter earnings report, despite beating estimates on the top and bottom lines.
Tempus Reports Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Is TEM Stock A Buy At $60?
Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock st...
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This ne...
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: A...
Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
SOPHIA ANTIPOLIS, France & CHICAGO--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI...
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full ...
Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new ...
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-mill...
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its ...
Tempus Logix Launches AI-Powered Calculator to End Hidden Fees and Price Fluctuation in Auto Transport
Tempus Logix Auto Transport launches an AI-powered calculator that delivers instant, exact car shipping prices with no hidden fees. Los Angeles, California--(Newsfile Corp. - January 26, 2026) - Tempu...
Tempus AI: Staying Bullish On Leading Healthcare AI Play
Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+...
Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare Conference
Tempus AI is reaffirmed as a Strong Buy, with profitability arriving a year earlier than consensus, driven by robust revenue growth and successful Ambry Genetics integration. TEM is guided to $1.59B r...
Tempus Announces the Launch of Paige Predict
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-...
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year...
Here's why the Tempus AI stock may surge 47% soon
Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. It has slumped to $66, with its market capitalization slumping from $17.8 billion in Octob...
Northwestern Medicine Selects Tempus to Expand Genomic Testing
CHICAGO--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provid...
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 bil...
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the f...